This has been disseminated by BioStem Technologies, Inc.
BSEM Could Be a Hidden Gem in Regenerative Medicine as Hospital Growth and Surgical Expansion Open a Much Bigger Opportunity!
BioStem Technologies (NASDAQ: BSEM) is building a much bigger story around its regenerative medicine platform, and the latest developments suggest the company is increasingly moving beyond traditional wound care and deeper into hospital-based surgical applications.
Following its BioTissue acquisition, BSEM is targeting specialties including urology, orthopedics, foot and ankle and other surgical procedures, while hospital revenue has become a major part of the business. With four GPO contracts providing access to a significant portion of U.S. hospital beds, an expanding commercial organization and more than 400 peer-reviewed publications supporting its technology and products, BSEM is building the infrastructure to pursue a much larger market opportunity!
But the growth story doesn’t stop at sales expansion. BSEM is also working to bring key manufacturing operations in-house, a move that could create an opportunity to improve margins as the acquired business scales.
Add in upcoming clinical publications, regulatory catalysts, new product opportunities and management’s focus on expanding its surgical footprint, and BSEM has several potential growth drivers converging at once. BSEM also recently made the move to Nasdaq, increasing its visibility among investors while attracting analyst attention and various price targets that point to potential upside as the company continues executing on its growth strategy.
For investors hunting for an under-the-radar biotech with a growing commercial platform and multiple shots on goal, BSEM is a name that could be worth watching closely.
See Why BSEM Could Be One of the More Intriguing Hidden Gems in Regenerative Medicine!
This message is a paid advertisement for Biostem Technologies, Inc. (BSEM) from Trading Wire and Sideways Frequency. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $14,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Trading Wire or Sideways Frequency. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Biostem Technologies, Inc. (BSEM) on Sideways Frequency' website for additional information about the relationship between Sideways Frequency and Biostem Technologies, Inc. (BSEM).
This Month's Exclusive News
IonQ Raised the Bar, But 3 Quantum Rivals Face Tough Questions
Authored by Nathan Reiff. Publication Date: 11/11/2026.
Key Points
- IonQ posted strong Q3 2026 results with revenue more than quadrupling year over year, setting a high bar that D-Wave, QCi, and Rigetti failed to match.
- D-Wave and Rigetti both reported widening operating losses and mounting expenses, contributing to steep year-to-date share price declines of over 50% each.
- Despite QCi's record quarterly revenue and large cash reserves, analysts remain cautious, as all three smaller quantum companies face lingering viability and growth concerns.
- Special Report: The biggest untaxed pile of money in America is yours
Early in November 2026, quantum computing pioneer IonQ Inc. (NYSE: IONQ) set a high bar with its Q3 2026 earnings report. Revenue more than quadrupled year over year (YOY), the company raised its full-year guidance again, and it reported a growing pile of contracts and cash reserves to fuel further growth. In the days that followed, other companies in the industry reported less impressive results. Earnings reports from D-Wave Quantum Inc. (NASDAQ: QBTS), Quantum Computing Inc. (NASDAQ: QUBT), and Rigetti Computing (NASDAQ: RGTI) all left something to be desired.
The quantum industry has tremendous technological potential, but the market appetite for these companies has been weakening, as evidenced by sharp declines in the share prices of many quantum stocks. A long timeline to commercialization, waning enthusiasm for the technology, stubbornly slow revenue growth (or worse, declining revenue), and the risk of share dilution are weighing on many of these firms.
D-Wave: Turning Revenue Around, But Not Enough
After a dreary Q2 2026, when D-Wave's revenue remained essentially flat while expenses rose quickly, the company returned to growth in Q3. Revenue climbed 21% year over year, led by strong performance in the company's professional services segment. In absolute terms, however, D-Wave is lagging behind IonQ. The company reported just $4.5 million in net revenue for the quarter, compared with $174 million for IonQ, including $83.5 million from SkyWater foundry services. IonQ has a larger market capitalization, but the widening revenue gap is still notable.
In Q2, D-Wave touted significant bookings growth, but bookings were no longer a highlight in Q3. During the latest quarter, bookings fell 19% year over year to $1.9 million, although they rose 611% in the first nine months of 2026. More importantly, D-Wave's costs continue to mount, with GAAP operating expenses rising 84% YOY and adjusted EBITDA losses increasing 83% over the same period to nearly $38 million.
D-Wave's professional services may be critical to driving widespread adoption of its quantum products, but this part of the business has lower margins. As revenue from the segment increased, the company's gross margin declined.
All of this points to a company that has yet to find a sustainable, scalable commercial model. Although the firm has ample cash, it has relied on dilutive measures to fund its growth. Investors unwilling to wait for D-Wave to determine its next steps over the coming years have largely sold their shares, contributing to a roughly 60% year-to-date (YTD) drop.
QCi: Impressive Revenue, But Viability Risks Persist
Quantum Computing, known as QCi, is a smaller company—less than half D-Wave's market capitalization and about a tenth of IonQ's—but in some ways its Q3 2026 earnings report was more promising than that of its larger rival. QCi reported record revenue of $9.5 million, up sharply from $0.4 million a year earlier and nearly $2 million above estimates. Acquired businesses accounted for much of the increase.
QCi's backlog is small but growing, reaching $39 million last quarter. However, the firm still faces significant lumpiness in both its backlog and realized revenue. As a result, even though QCi demonstrated impressive top-line growth this quarter, there is no guarantee the trend will continue.
Still, QCi has a strong reserve of $1.3 billion in cash, cash equivalents, and investments—enough to fund at least another year of operations. This is helpful, but the company still faces a potentially long and costly path to profitability. The risk to its viability may help explain why QUBT shares have an overall Hold rating across Wall Street.
Rigetti: Revenue Disappointment and Widening Losses Are Cause for Concern
If one quantum stock was especially disappointing in Q3 earnings, it may be Rigetti. Revenue fell more than a quarter YOY to just $1.4 million, putting the company last among these four companies for quarterly revenue and erasing any revenue growth momentum investors may have hoped for.
Lower revenue came alongside higher costs, with operating expenses climbing to $34 million and operating losses widening to more than $33 million. This trend would be difficult to sustain over the long term.
Rigetti's Cepheus-1-108Q processor is achieving important technological milestones, positioning the company for even bigger achievements over the next two years. While promising over the long term, this progress has not been enough to reverse the company's sizable share price decline in 2026. Shares remain down more than 45% YTD.
. |
